Insmed (INSM) Other Non Operating Income (2013 - 2026)
Insmed (INSM) posted quarterly Other Non Operating Income of -$736000.0 for Q1 2026, down 657.58% year-over-year from $132000.0 in Q1 2025, and up 59.63% quarter-over-quarter from -$1.8 million in Q4 2025.
Insmed (INSM) Other Non Operating Income (2013 - 2026) Analysis & Trends
Insmed's Other Non Operating Income history runs 14 years deep, the most recent figure standing at -$736000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 657.58% year-over-year to -$736000.0; the TTM figure through Mar 2026 stood at -$2.1 million (up 47.95% YoY), while the FY2025 annual figure was -$1.8 million, down 680.08% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$736000.0, up from -$1.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $3.5 million in Q4 2023, with the low at -$3.9 million in Q3 2024.
- The 5-year median for Other Non Operating Income is $10500.0 (2023), against an average of -$198000.0.
- The sharpest annual moves came in 2023 and 2024: Other Non Operating Income soared 210.27% in 2023, then plunged 1451.58% in 2024.
- Insmed's Other Non Operating Income stood at $1.1 million in 2022, then jumped by 210.27% to $3.5 million in 2023, then plunged by 120.25% to -$710000.0 in 2024, then plunged by 156.76% to -$1.8 million in 2025, then jumped by 59.63% to -$736000.0 in 2026.
- Business Quant data shows INSM's Other Non Operating Income at -$736000.0 in Q1 2026, -$1.8 million in Q4 2025, and $453000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -531,000.00 |
| Mar 31, 2026 | -736,000.00 |
| Dec 31, 2025 | -1.82 Mn |
| Jun 30, 2025 | 453,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Dec 31, 2024 | -710,000.00 |
| Sep 30, 2024 | -3.85 Mn |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | -1.10 Mn |
| Dec 31, 2023 | 3.51 Mn |
| Sep 30, 2023 | 285,000.00 |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | -111,000.00 |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | -1.51 Mn |
| Dec 31, 2021 | 14.36 Mn |
| Jun 30, 2021 | -17.69 Mn |
| Mar 31, 2021 | -43,000.00 |
| Sep 30, 2020 | -4,000.00 |
| Mar 31, 2020 | 36,000.00 |